New drug combo targets tough breast cancer in 40-Patient trial
NCT ID NCT05230810
First seen Mar 22, 2026 · Last updated May 13, 2026 · Updated 9 times
Summary
This study tests a combination of two drugs, tucatinib and alpelisib, in 40 adults with a specific type of advanced HER2-positive breast cancer that has a PIK3CA gene mutation. The goal is to see if the combo is safe and can slow cancer growth. Participants must have cancer that has spread or cannot be removed by surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Care & Hematology-Fort Collins
Fort Collins, Colorado, 80528, United States
-
Louisiana State University Health Sciences Center
New Orleans, Louisiana, 70112, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.